Guido Ghilardi

Guido Ghilardi is an Italian physician-scientist who graduated from the Univerista’ del Piemonte Orientale (Novara, Italy) and trained as a hematologist at the Oncology Institute of Southern Switzerland, a world-renowned center for the treatment of lymphomas, interested in adoptive immunotherapy, such as chimeric antigen receptor T cells (CART) immunotherapy. To study the mechanisms underlying resistance and toxicities of CART immunotherapy, Guido joined the Ruella’s laboratory at the Center for Cellular Immunotherapies at the University of Pennsylvania in 2020, where he works as a 4th year post-doctoral researcher. 

The focus of Guido’s research is to improve CART immunotherapy in non-Hodgkin lymphomas by studying the causes of resistance and the mechanisms underlying CART toxicities to design innovative and safer therapeutic approaches. Guido’s main focus is studying how different lymphodepletion regimens are able to generate different cytokine and metabolite environments by the time of CART infusion, and how these modifications contribute to the emergence of toxicities and ultimately propose safer lymphodepletion regimens. Moreover, Guido is evaluating new approaches to overcome resistance to CART immunotherapy by designing a new optimized dual CART product able to prevent the emergence of antigen-negative escape.